Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Liying Xing

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
BMJ (Clinical Research Ed.)|May 27, 2025
A village doctor-led mobile health intervention for cardiovascular risk reduction in rural China: cluster randomised controlled trialXingyi Zhang, Siming Wang, Xingyu Zhou, et al.
American Journal of Hypertension|February 19, 2021
Rationale and Design of a Cluster Randomized Trial of a Village Doctor-Led Intervention on Hypertension Control in ChinaYingxian Sun, Zhao Li, Xiaofan Guo, et al.
Lancet (London, England)|May 2, 2022
A village doctor-led multifaceted intervention for blood pressure control in rural China: an open, cluster randomised trialYingxian Sun, Jianjun Mu, Dao Wen Wang, et al.
Journal of the American College of Cardiology|July 8, 2026
Cardiovascular Health Change Patterns After Multifaceted Antihypertensive Intervention and Cardiovascular Outcomes: A Post Hoc Analysis of CRHCP TrialXiaofan Guo, Guozhe Sun, Ziyi Xie, et al.
Lancet (London, England)|March 5, 2023
Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trialJiang He, Nanxiang Ouyang, Xiaofan Guo, et al.
Scientific Reports|May 19, 2016
VEGF-B inhibits hyperglycemia- and Macugen-induced retinal apoptosisDelong Huang, Chen Zhao, Rong Ju, et al.
BMC Medicine|March 3, 2026
Cardiovascular outcomes of intensive blood pressure control in patients with and without metabolic dysfunction-associated fatty liver disease: post hoc analysis of the CRHCP trialSongyue Liu, Yangzhi Yin, Hongmei Yang, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 20, 2017
Critical role of caveolin-1 in ocular neovascularization and multitargeted antiangiogenic effects of cavtratin via JNKYida Jiang, Xianchai Lin, Zhongshu Tang, et al.
Oncotarget|October 28, 2016
PDGF-CC underlies resistance to VEGF-A inhibition and combinatorial targeting of both suppresses pathological angiogenesis more efficientlyLei Zheng, Chen Zhao, Yuxiang Du, et al.
Signal Transduction and Targeted Therapy|August 17, 2023
VEGF-B prevents excessive angiogenesis by inhibiting FGF2/FGFR1 pathwayChunsik Lee, Rongyuan Chen, Guangli Sun, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
BMJ (Clinical Research Ed.)|May 27, 2025
A village doctor-led mobile health intervention for cardiovascular risk reduction in rural China: cluster randomised controlled trialXingyi Zhang, Siming Wang, Xingyu Zhou, et al.
American Journal of Hypertension|February 19, 2021
Rationale and Design of a Cluster Randomized Trial of a Village Doctor-Led Intervention on Hypertension Control in ChinaYingxian Sun, Zhao Li, Xiaofan Guo, et al.
Lancet (London, England)|May 2, 2022
A village doctor-led multifaceted intervention for blood pressure control in rural China: an open, cluster randomised trialYingxian Sun, Jianjun Mu, Dao Wen Wang, et al.
Journal of the American College of Cardiology|July 8, 2026
Cardiovascular Health Change Patterns After Multifaceted Antihypertensive Intervention and Cardiovascular Outcomes: A Post Hoc Analysis of CRHCP TrialXiaofan Guo, Guozhe Sun, Ziyi Xie, et al.
Lancet (London, England)|March 5, 2023
Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trialJiang He, Nanxiang Ouyang, Xiaofan Guo, et al.
Scientific Reports|May 19, 2016
VEGF-B inhibits hyperglycemia- and Macugen-induced retinal apoptosisDelong Huang, Chen Zhao, Rong Ju, et al.
BMC Medicine|March 3, 2026
Cardiovascular outcomes of intensive blood pressure control in patients with and without metabolic dysfunction-associated fatty liver disease: post hoc analysis of the CRHCP trialSongyue Liu, Yangzhi Yin, Hongmei Yang, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 20, 2017
Critical role of caveolin-1 in ocular neovascularization and multitargeted antiangiogenic effects of cavtratin via JNKYida Jiang, Xianchai Lin, Zhongshu Tang, et al.
Oncotarget|October 28, 2016
PDGF-CC underlies resistance to VEGF-A inhibition and combinatorial targeting of both suppresses pathological angiogenesis more efficientlyLei Zheng, Chen Zhao, Yuxiang Du, et al.
Signal Transduction and Targeted Therapy|August 17, 2023
VEGF-B prevents excessive angiogenesis by inhibiting FGF2/FGFR1 pathwayChunsik Lee, Rongyuan Chen, Guangli Sun, et al.
Pageof 7